Novo Nordisk: extends collaboration with Gilead in NASH
(CercleFinance.com) - Denmark's Novo Nordisk announced on Thursday that it has extended its partnership with the American Gilead Sciences in the search for treatments against NASH, an increasingly frequent chronic liver disease.
Under the terms of the agreement, both groups plan to conduct a Phase 2b study to assess the safety and efficacy of the combination of semaglutide, Novo's diabetes treatment, and two investigational molecules discovered. by the Californian laboratory.
The trial is expected to include 440 patients with compensated cirrhosis, resulting from NASH, with first recruitments expected in the second half of the year.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Under the terms of the agreement, both groups plan to conduct a Phase 2b study to assess the safety and efficacy of the combination of semaglutide, Novo's diabetes treatment, and two investigational molecules discovered. by the Californian laboratory.
The trial is expected to include 440 patients with compensated cirrhosis, resulting from NASH, with first recruitments expected in the second half of the year.
Copyright (c) 2021 CercleFinance.com. All rights reserved.